

AKTIESPARARNA SHAREHOLDER EVENT

F.R. Martelet, M.D., CEO

15th September 2020

Forward-looking statement

IMPORTANT NOTICE

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Oasmia believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Oasmia include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

Oasmia - an innovation-focused specialty pharmaceutical company







Founded in **1999** HQ Uppsala, Sweden 26* employees

XR-17™ technology platform,

allowing micelle formulations of APIs, to be soluble in water - broad applications in oncology, human and animal health Lead product Apealea[®] approved in EU/EEA for advanced ovarian cancer, partner Elevar in discussions with FDA; global commercial deal worth up to \$698m + royalties



NASDAQ Stockholm 2010 Market Cap approx. SEK 2,2 B



R&D-certified Production Facility and R&D, in Uppsala, Sweden



New CEO in place since March 2020

Building a sustainable, profitable specialty pharma company

MEETING UNMET MEDICAL NEED		APEALEA [®] APPROVED IN EUROPE	A GLOBAL PARTNERSHIP
IMPROVING SOLUBILITY & SIDE EFFECT PROFILS OF ESTABLISHED & NOVEL CANCER DRUGS INCREASING R&D EFFICIENCY		LEAD PRODUCT LAUNCHED FOR ADVANCED OVARIAN CANCER	WORTH UP TO \$678 MILLION PLUS ROYALTIES
A GROWING PIPELINE		POSITIONED FOR M&A,	NEW MANAGEMENT &
	1		
UNDERPINNED BY STRONG IP PROTECTION		PROVEN DEVELOPMENT, REGULATORY AND BD SKILLS + SOLID CASH POSITION	FOCUSING RESOURCES TO BUILD A SUSTAINABLE, PROFITABLE BUSINESS



The new team leading Oasmia's transformation





FRANCOIS MARTELET, M.D., Master's Degree Business

Chief Executive Officer

Previous experience: CEO in Biotechnology/ BioPharma in UK, DNK, US and senior executive global roles at Novartis Oncology, Merck & Co., Inc with large P&L responsibility FREDRIK JÄRRSTEN* Chief Finance Officer

> REINHARD KOENIG, M.D. Acting Chief Medical Officer

ELIN TRAMPE, Chief Technical Officer

PETER SELIN* Chief Business Officer



ANDERS HÄRFSTRAND, M.D., PhD.

Non-executive Chairman


Previous experience: Experienced Pharma BoD, M&A experience, former executive positions in Pfizer, Pharmacia. Pharmacia & Upjohn

HEGE HELLSTRÖM, B.A. Board Member

PETER ZONABEND, LL.M, EMLE Board Member



Meeting the challenges of poor drug solubility




1) API = Active Pharmaceutical Ingredient - the ingredient in a pharmaceutical drug that is biologically active

2) Nikolakakis & Partheniadis





XR-17[™] - powerful platform that can increase solubility of insoluble compounds



XR-17[™] increases small molecule solubility and potentially improves safety and efficacy of new formulations

XR-17™ - a validated platform applicable in many therapeutic areas



Strong, validated safety in cancer indication¹



Drug load capacity, enabling high drug delivery capability



Shorter infusion time^{1,2}



Superior solubility compared with other platforms and technologies, enhances bioavailability of API




No mandatory or limited need for premedication¹



Free from alcohol, Cremophor EL, Polysorbate-80 and Human albumin, which can cause numerous side effects



XR-17[™] - multiple opportunities in oncology, human and animal health





Building a diverse portfolio based on XR-17[™] platform technology



Product	Indication	Pre-clinical	Phase I	Phase II	Phase III	Registration / approval	Geography
Human Health	Portfolio						
Apealea® / Paclical®	Ovarian cancer					Pre-NDA meeting	USA
(paclitaxel)	Ovarian cancer	_				 	EU / EEA ¹
Technology Pl	atform Portfoli	io	Planned				
Docetaxel micellar	Prostate cancer		T lumited				Global
New API	Undisclosed	_					Global
XR19 (combination)	Assessments in various cancers						Global
Animal Health	Portfolio						
Paccal vet (paclitaxel)	Mammary Carcinoma (Canines)				·	No	US
Doxophos vet (doxorubicin)						No	US

XR-17[™] - broad IP protection up to 2036



ANTICANCER PROCESS WATER-INSOLUBLE **COMPOSITIONS** Protects the Protects poorly water-Protects XR-17[™] in manufacturing process soluble APIs¹ in combination with for XR-17™ combination with XRchemotherapeutic 17TM agents patents patents granted application across Euragia, European Patent Office, AUS, CAN, GBR, DEU, granted CHN and CHN, HKG, JPN, KOR, MEX, MYS, NZL, UKR, USA, ZAF HKG applied for in patents the EU, granted pending (5-year extension) Application pending in Eurasia, European Patent Office, AUS, BRA, CAN, CHN, IND, IDN, JPN, MYS,



MEX, NZL, KOR, SGP and UKR



Apealea® - offering improved treatment options





Approved in EU/EEA for treatment of first relapse ovarian cancer¹ and in Russia for first line and relapsed ovarian cancer²

Current standard of care in Ovarian cancer is carboplatin + paclitaxel

Subset of patients cannot tolerate solvent-based paclitaxel

Apealea[®] is an IV injectable formulation using XR-17[™] which facilitates solubility of paclitaxel









🎖 oasmia

The growing taxane market for ovarian and other cancers

The 2018 global injectable taxane market was valued at \$2.18B The market is expected to grow \$4.56B by the end of 2025 (CAGR 11% 2019 - 2025)

Taxol®

- Paclitaxel cremophor EL
- Ovarian, breast, lung and Kaposi Sarcoma cancers
- Best selling drug of all time with annual sales of \$1.6B prior to patent expiration (2000)

Abraxane[®]

- Paclitaxel albumin bound
- Breast, lung and pancreatic cancers
- \$1.35B (2019)



Taxotere[®]

- Docetaxel polysorbate 80
- Breast, lung, prostate and head & neck cancers
- Peak sales \$3B (2010)
- ~\$170M (2019)

Jevtana®

Apealea[®] is the only non-cremophor drug approved for use in

advanced stage ovarian cancer in the EU

- Cabazitaxel polysorbate
 80
- Prostate cancer
- ~\$480M (2019)










Apealea® - multiple benefits compared to the competition

	apealea paclitaxel (micellar)	Taxol [®]	Abraxane® nanoparticle albumin bound paclitaxel	Lipusu®	Genexol-PM [®] Korea
Company	oasmia	ز ^{ال} ا Bristol Myers Squ	libb [™] (Celgene	LUYE PHARMA	samyang Biopharm
Indication	Ovarian Cancer	Ovarian Cancer Breast Cancer NSCLC	Breast Cancer	Ovarian Cancer Breast Cancer NSCLC	Ovarian Cancer Breast Cancer NSCLC
Infusion Solution	Micellar Solution	Emulsion	Colloidal Suspension	Liposome	Micellar Solution
Particle Size	25nm	10-22nm	130nm	400nm	~25nm
Excipient	XR-17™	Cremophor EL	Human Albumin	Lecithin/Cholesterol	PEG-PDLLA
Dose	250mg/m ²	175mg/m ²	260mg/m ²	175mg/m ²	260mg/m ²
Ratio (Excipient : API)	1.3:1.0	88.0:1.0	9.0:1.0	-	5.0:1.0
Infusion Time	1h	3h	<1h	3h	0.5h
Pre-medication	Not mandatory	Yes	No	Yes	No
Hypersensitivity	No	Yes	No	Yes	No



Apealea® - meeting unmet medical needs in selected ovarian cancer



295,000 women diagnosed in 2018 - 8th most common cancer in

70% of women have a relapse three years after

Platinum analogs

used alone or in combination with paclitaxel are the most used therapeutic

2) Springerplus. 2016; 5(1): 1197. Published online 2016 Jul 28. doi: 10.1186/s40064-016-2660-0 3) ESMO guidelines: Annals of Oncology 30: 672-705, 2019 doi:10.1093/annonc/mdz062 Published

Apealea® - global partnership worth up to \$698m + royalties





Agreement with US-based Elevar Therapeutics, subsidiary of South Korea's HLB

\$20_M

Upfront payment

%

Double digit royalties on global Apealea® sales

\$678M

Milestones based on regulatory and sales achievements



Oasmia retains sole control over development of XR-17™ in other APIs



Named patient program initiated with Tanner Pharma Group ex US Elevar considering European partners for commercial sales



Docetaxel micellar in clinical development

- Prostate cancer is a leading cause of cancer death in men worldwide
- Widely approved for wide range of solid malignancies and standard of care for advanced prostate cancer
- Docetaxel micellar uses XR-17[™], enabling IV administration of water-insoluble compounds without traditional solubility enhancers
- Being investigated for advanced prostate cancer in a Phase I clinical trial with the Swiss Group for Clinical Cancer Research (SAKK)







Why invest in Oasmia?



Multiple potential near and mid-term catalysts & value drivers...

- Elevar partnering for Apealea[®] in Europe, China
- Apealea[®] royalties
- Docetaxel micellar Phase 1 initiation
- Review of Animal Health assets
- XR-17[™] partnering
- M&A opportunities
- XR-19 value assessment

Mid-term (12-24 months)

- Apealea[®] milestones and royalties
- Docetaxel micellar Phase 1 results / potential Phase 2 initiation
- Potential initiation of XR-19 program
- Strengthening of balance sheet through existing cost control measures
- M&A and in-licensing opportunities to build critical mass

Sustaining Oasmia's transformation since CEO appointment

• Strategic

- Working progress on
 - Achieving Elevar deal milestones
 - Creating revenue opportunities for the animal health business and for XR-17[™]

Human Resources

- Reviewed and implemented right-sizing of the organization
- Strengthened management team with C level hires

• Operational

- Articulated and implemented docetaxel micellar clinical development plan incl. a collaborative agreement with SAKK
- Preclinical work with new API and XR-19 on-going
- Starting up a Patient Access Program in the EU through Elevar

• Financials

- Implemented cost savings of SEK 100m and burn rate of less than SEK 10m/month
- Resolved large corporate liabilities
- Investor Relations
 - Broadened research coverage

Opportunity to build long-term, profitable specialty pharma company through

in nease nate, many and in neensing of late stage assets

Solid foundations in place to build a profitable speciality pharma company



Realising our vision for success

Platform to build a Sweden-based cash-flow positive specialty pharma leader

Well placed for M&A and licensing collaborations